Gene therapy injection shows promise for blinding eye disease
Disease control
Completed
This early-stage study tested a new gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration, a leading cause of vision loss. The treatment aims to block abnormal blood vessel growth and leakage in the eye. The main goal was to check if the therapy is…
Phase: PHASE1 • Sponsor: Exegenesis Bio • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC